Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 18, 2025 09:22 ET | Source: Research and Markets

Pancreatic Cancer Pipeline Analysis Report Featuring Key Players - Pfizer, Sanofi, Novartis Pharmaceuticals, Bristol-Myers Squibb, Eisai, AstraZeneca, GlaxoSmithKline, F-Hoffmann-La Roche

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pancreatic Cancer Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.The pancreatic cancer drug pipeline analysis...
March 28, 2024 11:19 ET | Source: Research and Markets

Global Colorectal Cancer Drugs Market to Reach USD 12.79 Billion by 2028 with Notable CAGR of 4.57%

Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Global Colorectal Cancer Drugs Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis."...
March 06, 2024 04:09 ET | Source: Research and Markets

Capecitabine Global Market Report 2024

Dublin, March 06, 2024 (GLOBE NEWSWIRE) -- The "Capecitabine Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The capecitabine market size is expected to see...
January 09, 2024 18:48 ET | Source: Research and Markets

Capecitabine Market Research Reveals Significant Growth in Oncology Treatment Sector

Dublin, Jan. 09, 2024 (GLOBE NEWSWIRE) -- The "Capecitabine Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The latest market research on capecitabine, a...
December 19, 2023 09:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved...
December 07, 2023 06:30 ET | Source: Research Nester

Cholangiocarcinoma Market revenue to hit USD 1.3 Billion by 2036, says Research Nester

New York , Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global cholangiocarcinoma market size is projected to grow at a CAGR of over 4% from 2024 to 2036. The market is expected to garner a revenue of USD...
August 29, 2023 11:00 ET | Source: CONSEGIC BUSINESS INTELLIGENCE PRIVATE LIMITED

Capecitabine Market to Hit US$ 1,558.74 Million By 2030 | Updated Analysis

New York, Aug. 29, 2023 (GLOBE NEWSWIRE) -- The global Capecitabine Market is expected to witness significant growth at a remarkable CAGR of 5.5% during the forecast period of 2023-2030. The factors...
May 18, 2023 08:00 ET | Source: Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

HANOVER, MD, May 18, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) today announces it has received guidance from the U.S. Food and Drug...
December 31, 2021 05:48 ET | Source: Research and Markets

Investigation Report on China's Capecitabine Market 2021-2025 Featuring Shanghai Roche Pharma, Jiangsu Hengrui Medicine , Qilu Pharma, Chia Tai Tianqing Pharma Group & Hoffmann-La Roche

Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Capecitabine Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. Capecitabine is a pyrimidine...
September 19, 2019 03:50 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO

- Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8...